Composition and method for producing a transparent thermoplastic polycarbonate/polymethyl methacrylate moulding compound

    公开(公告)号:US12195623B2

    公开(公告)日:2025-01-14

    申请号:US18575903

    申请日:2022-06-27

    Abstract: The present invention relates to a composition for producing a thermoplastic moulding compound containing: A) an aromatic polycarbonate and/or aromatic polyester carbonate containing carboxy groups, wherein the polycarbonate has an acid value ranging from 0.5 to 10 mg of potassium hydroxide/g, determined in dichloromethane/ethanol as the solvent by means of potentiometric titration in accordance with DIN EN ISO 2114, method A in version 2002-06 with ethanolic potassium hydroxide solution at ambient temperature, and a weight-average molecular mass (Mw), determined by gel permeation chromatography at ambient temperature in dichloromethane as the solvent using a BPA polycarbonate standard, ranging from 15,000 to 40,000 g/mol, and B) a polymethyl methacrylate copolymer containing structural units derived from glycidyl methacrylate, wherein the copolymer has an epoxide equivalent weight, determined in dichloromethane as the solvent at ambient temperature in accordance with DIN EN 1877-1 in version 2000-12, of 0.05 to 3 wt % and a weight-average molecular mass (Mw), determined by gel permeation chromatography at ambient temperature in tetrahydrofuran as the solvent using a polystyrene standard, of 20,000 to 200,000 g/mol, wherein the weight ratio of component A and component B ranges from 95:5 to 35:65, and a method for producing a moulding compound from the composition, a moulding compound obtained according to the method, the use of the moulding compound to produce moulds, the moulds per se and a method for producing the moulds.

    FACTORS CONTROLLING DRUG RELEASE IN CROSS-LINKED POLY(VALEROLACTONE) BASED MATRICES

    公开(公告)号:US20240368351A1

    公开(公告)日:2024-11-07

    申请号:US18508042

    申请日:2023-11-13

    Abstract: The present disclosure relates to controlling drug release in cross-linked poly(valerolactone) based matrices. In one aspect, the compounds or pharmaceutically acceptable salts thereof include a poly(valerolactone)-co-poly(allylvalerolactone)-co-polyethylene glycol (PEG) copolymer. In some embodiments, at least a portion of allylvalerolactone residues within the copolymer are crosslinked with a crosslinker. In some embodiments, the compound has a polydispersity index of less than or equal to 1.5. In one aspect, a method is described herein, comprising: (a) polymerizing valerolactone residues, allylvalerolactone, and polyethylene glycol residues in the presence of a non-metal catalyst via a ring opening polymerization to produce a poly(valerolactone)-co-poly(allylvalerolactone)-co-polyethylene glycol copolymer; (b) crosslinking the poly(valerolactone)-co-poly(allylvalerolactone)-co-polyethylene glycol copolymer with a crosslinker; and (c) loading a drug into the crosslinked copolymer. In some embodiments, the compound can comprise amorphous networks. In some embodiments, the compound can include semi-crystalline networks.

Patent Agency Ranking